Femasys (NASDAQ:FEMY – Get Free Report) is expected to be announcing its earnings results before the market opens on Thursday, March 27th. Analysts expect the company to announce earnings of ($0.25) per share for the quarter.
Femasys Trading Up 2.6 %
Femasys stock opened at $1.60 on Wednesday. The business has a 50 day moving average price of $1.39 and a two-hundred day moving average price of $1.22. The company has a quick ratio of 3.26, a current ratio of 3.94 and a debt-to-equity ratio of 0.86. Femasys has a 12 month low of $0.86 and a 12 month high of $1.84. The stock has a market cap of $36.64 million, a price-to-earnings ratio of -1.98 and a beta of -2.85.
Analysts Set New Price Targets
Separately, HC Wainwright upped their target price on Femasys from $12.00 to $15.00 and gave the company a “buy” rating in a research note on Wednesday, March 19th.
Femasys Company Profile
Femasys Inc, a biomedical company, develops therapeutic and diagnostic solutions to address unmet women healthcare needs worldwide. The company provides FemVue saline-air device, a contrast-generating product in the United States, Canada, Japan, and Hong Kong; FemCath, a cornual balloon catheter, a single intrauterine directional delivery product that allows for selective evaluation of an individual fallopian tube; and FemCerv, a biopsy device for endocervical curettage, which can be used to sample cervical cells and tissue circumferentially with sample containment within the device to minimize contamination.
Read More
- Five stocks we like better than Femasys
- Comparing and Trading High PE Ratio Stocks
- Innovation Incubators: Survey of Entrepreneurs Reveals The Cities Most Supportive of Startups
- How to find penny stocks to invest and trade
- NVIDIA Insiders Sell: This Is What It Means for the Market
- How to invest in marijuana stocks in 7 steps
- Space Stocks Bottoming: Which Are Positioned Best for a Bounce?
Receive News & Ratings for Femasys Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Femasys and related companies with MarketBeat.com's FREE daily email newsletter.